MX2023009754A - Formulaciones de microesferas que comprenden lurasidona y metodos para fabricar y usar las mismas. - Google Patents

Formulaciones de microesferas que comprenden lurasidona y metodos para fabricar y usar las mismas.

Info

Publication number
MX2023009754A
MX2023009754A MX2023009754A MX2023009754A MX2023009754A MX 2023009754 A MX2023009754 A MX 2023009754A MX 2023009754 A MX2023009754 A MX 2023009754A MX 2023009754 A MX2023009754 A MX 2023009754A MX 2023009754 A MX2023009754 A MX 2023009754A
Authority
MX
Mexico
Prior art keywords
lurasidone
making
methods
same
microsphere formulations
Prior art date
Application number
MX2023009754A
Other languages
English (en)
Spanish (es)
Inventor
Tracy Richey
Mark Smith
Colin Spencer
Griffin Beyer
Nicholas Delucia
Original Assignee
Oakwood Laboratories LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oakwood Laboratories LLC filed Critical Oakwood Laboratories LLC
Publication of MX2023009754A publication Critical patent/MX2023009754A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MX2023009754A 2021-02-24 2022-02-24 Formulaciones de microesferas que comprenden lurasidona y metodos para fabricar y usar las mismas. MX2023009754A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163152943P 2021-02-24 2021-02-24
US202263267403P 2022-02-01 2022-02-01
PCT/US2022/070807 WO2022183196A1 (en) 2021-02-24 2022-02-24 Microsphere formulations comprising lurasidone and methods for making and using the same

Publications (1)

Publication Number Publication Date
MX2023009754A true MX2023009754A (es) 2023-08-30

Family

ID=82900191

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023009754A MX2023009754A (es) 2021-02-24 2022-02-24 Formulaciones de microesferas que comprenden lurasidona y metodos para fabricar y usar las mismas.

Country Status (9)

Country Link
US (1) US11992559B2 (cg-RX-API-DMAC7.html)
EP (1) EP4297753A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024507528A (cg-RX-API-DMAC7.html)
KR (1) KR20230157365A (cg-RX-API-DMAC7.html)
AU (1) AU2022226584A1 (cg-RX-API-DMAC7.html)
CA (1) CA3210098A1 (cg-RX-API-DMAC7.html)
IL (1) IL304650A (cg-RX-API-DMAC7.html)
MX (1) MX2023009754A (cg-RX-API-DMAC7.html)
WO (1) WO2022183196A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240307381A1 (en) * 2021-02-24 2024-09-19 Oakwood Laboratories, Llc Microsphere formulations comprising lurasidone and methods for making and using the same
CN119424341A (zh) * 2023-08-02 2025-02-14 珠海市华海康医药科技有限责任公司 一种注射用药物缓释微球及其制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60100516A (ja) 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
US5288502A (en) 1991-10-16 1994-02-22 The University Of Texas System Preparation and uses of multi-phase microspheres
EP0724432B1 (en) 1993-10-22 2002-09-18 Genentech, Inc. Methods and compositions for microencapsulation of antigens for use as vaccines
ATE288270T1 (de) 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
WO2005003180A2 (en) 2003-04-10 2005-01-13 Pr Pharmaceuticals A method for the production of emulsion-based micro particles
AU2004259208B2 (en) 2003-07-15 2011-04-28 Evonik Corporation Method for the preparation of controlled release formulations
EP1660039B1 (en) 2003-07-18 2016-09-28 Oakwood Laboratories L.L.C. Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions
AU2004259209A1 (en) 2003-07-23 2005-02-03 Pr Pharmaceuticals, Inc. Controlled release compositions
EP1891956B1 (en) 2005-06-13 2012-08-29 Dainippon Sumitomo Pharma Co., Ltd. Solubilization preparation
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
ES2420479T3 (es) 2006-08-31 2013-08-23 Sk Chemicals, Co., Ltd. Procedimiento para la producción de microesferas cargadas con fármacos y microesferas cargadas con fármacos producidas mediante el mismo
EP2222281B1 (en) 2007-12-20 2018-12-05 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
KR20120035183A (ko) 2009-06-10 2012-04-13 선오비온 파마슈티컬스 인코포레이티드 히스타민 h3 역 작용제 및 길항제, 및 이의 사용 방법
EP2521711B1 (en) 2010-01-07 2017-08-16 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
US10335366B2 (en) * 2010-05-31 2019-07-02 Laboratorios Farmacéuticos Rovi, S.A. Risperidone or paliperidone implant formulation
US9469630B2 (en) 2010-10-18 2016-10-18 Sumitomo Dainippon Pharma Co., Ltd. Sustained-release formulation for injection
US9616031B2 (en) 2010-11-24 2017-04-11 Nanyang Technological University Method for encapsulating particles
JP6013364B2 (ja) 2010-12-23 2016-10-25 アルカーメス ファーマ アイルランド リミテッド マルチプルapiローディングプロドラッグ
US9999670B2 (en) 2012-03-19 2018-06-19 Alkermes Pharma Ireland Limited Pharmaceutical compositions comprising benzyl alcohol
WO2014076712A2 (en) 2012-11-14 2014-05-22 Hetero Research Foundation Lurasidone hydrochloride solid dispersion
WO2014144309A1 (en) * 2013-03-15 2014-09-18 Oakwood Laboratories Sustained release microspheres and method of producing the same
US9636308B2 (en) 2013-03-15 2017-05-02 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
US9393211B2 (en) 2013-03-15 2016-07-19 Oakwood Laboratories LLC High drug load buprenorphine microspheres and method of producing same
PT3010962T (pt) * 2013-06-20 2017-09-05 Pharmathen Sa Preparação de micropartículas polilactida-poliglicolida com um perfil de libertação sigmoide
KR102967223B1 (ko) * 2013-12-03 2026-05-19 인트라-셀룰라 써래피스, 인코퍼레이티드. 신규한 방법
US20150157628A1 (en) 2013-12-11 2015-06-11 Saravanan Kannusamy Pharmaceutical compositions of Lurasidone and Process for preparation thereof
CN107205939B (zh) 2015-01-05 2020-11-06 波士顿科学国际有限公司 用于实体瘤治疗的可生物降解的药物洗脱微球
US20190046532A1 (en) 2015-09-30 2019-02-14 Indivior Uk Limited Psychiatric treatment for patients with gene polymorphisms
WO2017119928A1 (en) 2016-01-08 2017-07-13 Abon Pharmaceuticals, Llc Long acting injectable formulations
WO2018015915A1 (en) 2016-07-22 2018-01-25 Cadila Healthcare Limited A parenteral controlled release composition of an atypical antipsychotic agent

Also Published As

Publication number Publication date
JP2024507528A (ja) 2024-02-20
KR20230157365A (ko) 2023-11-16
CA3210098A1 (en) 2022-09-01
EP4297753A1 (en) 2024-01-03
WO2022183196A1 (en) 2022-09-01
AU2022226584A1 (en) 2023-08-17
US11992559B2 (en) 2024-05-28
US20220265562A1 (en) 2022-08-25
EP4297753A4 (en) 2025-01-01
IL304650A (en) 2023-09-01

Similar Documents

Publication Publication Date Title
BR0314356A (pt) Formulações de liberação retardada para administração oral de um agente terapêutico polipetìdeo e métodos utilizando as mesmas
ECSP105739A (es) Anticuerpos de neutralización contra gdf-8
MX2020010369A (es) Particulas implantables y metodos relacionados.
NO20012774D0 (no) Preparat og metode hvor det gjöres bruk av eteriske planteoljer
BRPI0514199A (pt) método de efetuar profilaxia ou tratar uma doença, composição farmacêutica, anticorpo monoclonal, célula de hibridoma, e, método de triar um agente, de humanizar anticorpo monoclonal 8a5 ou anticorpo monoclonal 6h7 e de produzir uma forma quimérica de anticorpo monoclonal 8a5 ou anticorpo monoclonal 6h7
DK0760848T3 (da) Lactobacillusstammer af menneskelig oprindelse, deres sammensætninger og anvendelse deraf
MXPA06014196A (es) Metodos y aparatos para la conservacion osea.
JO3324B1 (ar) مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
AU2003297260A1 (en) Fast-disintegrating solid dosage forms being not friable and comprising pullulan
TR200101699T2 (tr) Urogenital enfeksiyonların önlenmesi ve tedavisi için ağızdan lactobakilus uygulaması
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
MX2025008092A (es) Inhibidores de kif18a y usos de los mismos
PL356846A1 (en) Use of interleukin-6 antagonists for the treatment of diseases characterised by high levels of aromatase
MY209530A (en) Methods and compositions for the treatment of hair loss
MX2023005971A (es) Metodos y composicion para las modificaciones de kras.
SG10201802129QA (en) A pharmaceutical composition for neuropathic pain
WO2006093857A3 (en) Method of providing readily available cellular material derived from peripheral blood and a composition thereof
AR037556A1 (es) Composicion farmaceutica que comprende un abridor del canal de c1c-2
DK1274464T3 (da) Sammensætninger og fremgangsmåder til regulering af proteinekspression i tarm
TW200635603A (en) Therapeutic formulations of keratinocyte growth factor
NZ804686A (en) Substituted naphthyl p38alpha mitogen-activated protein kinase inhibitors
MX2025015454A (es) Formulaciones/composiciones que comprenden ibrutinib
DK1189627T3 (da) Sammensætninger indeholdende opløselige former af HLA-G til behandling af inflammatoriske patologiske tilstande i huden
ZA202209925B (en) Compositions and methods for treating pompe disease
MX2022004055A (es) Composicion novedosa para el cuidado de la piel.